Latest revenue
$6.2M
as of 2026-03-31
Latest net income
$-50.0M
as of 2026-03-31
Net margin
-802.7%
as of 2026-03-31
Community sentiment
Where do you think STOK is heading?
Keep private notes on STOK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
STOK vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $1.83B
- Enterprise value
- $1.67B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 4.63×
- Dividend yield
- 0.0%
- 52-wk high
- $40.22
- 52-wk low
- $11.12
- Beta
- —
- Shares out
- 62.3M
What this company does
Item 1. Business. Overview We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning…
AI summary unavailable — showing raw filing excerpt
Generated from STOK's filing dated 2026-03-16
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this annual report, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that…
AI summary unavailable — showing raw filing excerpt
Generated from STOK's filing dated 2026-03-16
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.